Analyst Rating
based on 23 analysts
40.91%
Buy
22.73%
Hold
36.36%
Sell
Based on 23 analysts offering long term price targets for Dr Lal Pathlabs Ltd. An average target of ₹3134.09
Source: S&P Global Market Intelligence
Dr Lal Pathlabs Ltd Share analysis
Dr Lal Pathlabs Ltd price forecast by 23 analysts
Downside of
High
₹3770
Target
₹3134.09
Low
₹2286
Dr Lal Pathlabs Ltd target price ₹3134.09, a slight downside of -7.72% compared to current price of ₹3416.8. According to 23 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Dr Lal Pathlabs Ltd revenue growth forecast
Expected growth rate Q1, FY2026:26.26%
Forecast
Actual
Including amortisation and stock based compensations
Dr Lal Pathlabs Ltd EPS growth forecast
EPS estimate Q1, FY2026:40.91%
Forecast
Actual
Source: S&P Global Market Intelligence
Performance
Day's Low
Day's High
₹3,405.1₹3,436.152 Week's Low
52 Week's High
₹1,943.7₹3,459.4
| Returns % | |
| 1 Month Return | + 5.24 % |
| 3 Month Return | + 23.41 % |
| 1 Year Return | + 53.96 % |
| Market Stats | |
| Previous Close | ₹3,396.15 |
| Open | ₹3,409.70 |
| Volume | 1.85L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹28,383.07Cr |
Key Statistics
| P/E Ratio | 74.07 |
| PEG Ratio | 5.27 |
| Market Cap | ₹28,383.07 Cr |
| P/B Ratio | 9.94 |
| EPS | 43.4 |
| Dividend Yield | 0.8 |
| Sector | Healthcare |
| ROE | 21.42 |
Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹28,383.07 Cr | 31.88% | 0.55 | ₹362 Cr | ₹2,226 Cr | |
| HOLD | ₹27,324.59 Cr | 127.35% | 0.67 | ₹168 Cr | ₹5,040 Cr | |
| HOLD | ₹75,062.31 Cr | 48.67% | 0.56 | ₹1,811 Cr | ₹12,667 Cr | |
| BUY | ₹9,408.41 Cr | 9.57% | 0.64 | ₹119 Cr | ₹547 Cr | |
| BUY | ₹4,508.39 Cr | 16.08% | 0.54 | ₹69 Cr | ₹571 Cr |
Company Information
The company's top products include pathology tests, imaging tests, and preventive health check-ups. Its popular brands include Dr Lal PathLabs, Lal PathLabs, and Lal PathLabs Diagnostics. Dr Lal PathLabs Ltd has over 2000 labs across India, with more than 2000 collection centers, and over 20000 trained professionals. The company is also present in Nepal, Sri Lanka, and Bangladesh.
Dr Lal PathLabs Ltd is committed to providing quality healthcare services and products to its customers. It is ISO 9001:2015 certified and has been accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL).
Share Price: ₹3416.80 per share as on 12 Sep, 2024 04:01 PM
Market Capitalisation: ₹28,383.07Cr as of today
Revenue: ₹601.90Cr as on June 2024 (Q2 24)
Net Profit: ₹107.80Cr as on June 2024 (Q2 24)
Listing date: 23 Dec, 2015
Chairperson Name: Arvind Lal
| Organisation | Dr Lal Pathlabs Ltd |
| Headquarters | Gurgaon |
| Industry | Healthcare |
| E-voting on shares | Click here to vote |
Key events for Dr Lal Pathlabs Ltd
Citi Issues Sell Call on Dr Lal PathLabs - 23 Aug, 2024
Citi has issued a sell call on Dr Lal PathLabs with a target price of ₹2,700 per share. The firm expects improved test mix and geographic expansion to drive better-than-industry growth, while noting no near-term price increases. Operating efficiencies may stabilize margins despite ongoing competition.
Dr. Lal Pathlabs Appoints New CEO for International Business - 13 Aug, 2024
Dr. Lal Pathlabs has re-designated Ved Prakash Goel as Group CFO and CEO – International Business effective August 13, 2024. The company reported a 28.9% profit growth in Q1, reaching Rs 107.80 crore, with revenue up 11.3% to Rs 601.90 crore, exceeding estimates.
Dr Lal Pathlabs Maintains Growth Amid Strategic Expansion - 09 Aug, 2024
Dr Lal Pathlabs reported a 9.3% YoY increase in sample volume and a 4.3% rise in patient volume. The company plans to open 20 new labs and focuses on non-communicable disease testing. Despite a recent downgrade to HOLD, the target price is raised to INR 3,240. The stock has gained 41% in the last three months.
Dr Lal Pathlabs Reports Earnings, Shares Decline - 08 Aug, 2024
Dr Lal Pathlabs posted strong Q1 FY25 results with revenue of Rs 602 crore and a 29% profit increase. However, shares fell 4% due to valuation concerns, prompting downgrades from brokerages like ICICI Securities (target price Rs 3,240) and JM Financial (target price Rs 3,425).
Dr Lal PathLabs Reports Strong Q1 Earnings - 07 Aug, 2024
Dr Lal PathLabs announced a 29% increase in Q1 profit to Rs 108 crore, driven by revenue growth to Rs 602 crore. An interim dividend of Rs 6 per share was also declared. Shares rose by 3.17% to Rs 3,268.85.
Experts Suggest Buying Dr Lal PathLabs Stock on Dips - 30 Jul, 2024
Dr Lal PathLabs Ltd, part of the healthcare sector, has recorded a breakout from an inverse Head & Shoulder pattern on monthly charts. Experts suggest short-to-medium term traders can buy the stock on dips for a possible target of above Rs 3,700 levels in the next few months.
Dr Lal Pathlabs Target Price Set at Rs 3,516 - 29 Jul, 2024
Dr Lal Pathlabs is expanding its presence in Mumbai and select parts of Maharashtra via Suburban. The company aims to strengthen operations through sampling promotion and brand building while developing new lab towns under the DLPL brand. Its strategic focus areas including geographical expansion, portfolio diversification, and digital transformation are driving significant progress. Analysts expect the stock to reach a price target of Rs 3,516 in 8-10 months.
Insights on Dr Lal Pathlabs Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPrice Rise
In the last 6 months, LALPATHLAB stock has moved up by 62.2%
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 557.2 Cr → 622.5 Cr (in ₹), with an average increase of 5.3% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 6.79% to 9.30% in Jun 2024 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, 81.3 Cr → 106.4 Cr (in ₹), with an average increase of 12.2% per quarter
NO EFFECTAgainst Peers
In the last 1 year, Fortis Healthcare Ltd has given 69.1% return, outperforming this stock by 15.2%
- NO EFFECT
Against Peers
In the last 3 years, Max Healthcare Institute Ltd has given 126.9% return, outperforming this stock by 145.5%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 54.60% of holdings in Jun 2024 quarter
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 26.15% to 25.42% in Jun 2024 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 9.24% to 6.96% in Jun 2024 quarter
Dr Lal Pathlabs Ltd Infographics
Dr Lal Pathlabs Ltd Q1 FY2024-2025 Results: Key Insights
Dr. Lal Pathlabs' profit surge 29% on strong demand for its medical tests in smaller cities
Company Financials
Index Inclusions
Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 54.6% | 0.00 | |
| Foreign Institutions | 25.42% | ||
| Mutual Funds | 9.3% | 36.88 | |
| Retail Investors | 6.96% | ||
| Others | 3.72% | 15.61 |
Key Indicators
Dr Lal Pathlabs Ltd Valuation
Dr Lal Pathlabs Ltd in the last 5 years
Lowest (37.51x)
November 16, 2018
Today (74.07x)
September 11, 2024
Industry (95.21x)
September 11, 2024
Highest (95.62x)
November 5, 2020
Earnings and Dividends
Dr Lal Pathlabs Ltd Earnings Results
Dr Lal Pathlabs Ltd’s net profit jumped 28.81% since last year same period to ₹106.40Cr in the Q1 2024-2025. On a quarterly growth basis, Dr Lal Pathlabs Ltd has generated 25.92% jump in its net profits since last 3-months.
Read More about Earnings ResultsDr Lal Pathlabs Ltd Dividends August,2024
In the quarter ending June 2024, Dr Lal Pathlabs Ltd has declared dividend of ₹6 - translating a dividend yield of 0.71%.
Read More about Dividends
Technicals Summary
Bearish
Neutral
Bullish
Dr Lal Pathlabs Ltd is currently in a Bullish trading position according to technical analysis indicators.
Frequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Dr Lal Pathlabs Ltd shares.
Dr Lal Pathlabs Ltd (LALPATHLAB) share price today is ₹3416.8
Dr Lal Pathlabs Ltd is listed on NSE
Dr Lal Pathlabs Ltd is listed on BSE
- Today’s highest price of Dr Lal Pathlabs Ltd is ₹3436.1.
- Today’s lowest price of Dr Lal Pathlabs Ltd is ₹3405.1.
PE Ratio of Dr Lal Pathlabs Ltd is 74.07
PE ratio = Dr Lal Pathlabs Ltd Market price per share / Dr Lal Pathlabs Ltd Earnings per share
Today’s traded volume of Dr Lal Pathlabs Ltd(LALPATHLAB) is 1.85L.
Today’s market capitalisation of Dr Lal Pathlabs Ltd(LALPATHLAB) is ₹28383.07Cr.
| Dr Lal Pathlabs Ltd(LALPATHLAB | Price |
|---|---|
52 Week High | ₹3459.4 |
52 Week Low | ₹1943.7 |
Dr Lal Pathlabs Ltd(LALPATHLAB) share price is ₹3416.8. It is down -1.23% from its 52 Week High price of ₹3459.4
Dr Lal Pathlabs Ltd(LALPATHLAB) share price is ₹3416.8. It is up 75.79% from its 52 Week Low price of ₹1943.7
| Dr Lal Pathlabs Ltd(LALPATHLAB | Returns |
|---|---|
1 Day Returns | 20.65% |
1 Month Returns | 5.24% |
3 Month Returns | 23.41% |
1 Year Returns | 53.96% |